Since mutations in the catalytic domain of UBE3A are sufficient for development of Angelman syndrome (Kishino et al., 1997; Matsuura et al., 1997; Cooper et al., 2004), the lack of ubiquitination and degradation of UBE3A substrates is predicted to increase these substrate protein levels. This evidence concerns the gene UBE3A and Angelman syndrome.